

CLAIMS

What is claimed is:

- Sub
B3
1. An isolated and purified glycoprotein and functional analogues thereof characterized by:
- (a) being expressed on at least primitive hematopoietic cells,
- (b) being a ligand for L-selectin, the binding of ligand to L-selectin not being inhibited by anti-CD34 antibodies;
- 10 (c) being resistant to O-sialoglycoprotein endopeptidase activity;
- (d) not being recognized by MECA-79 a monoclonal antibody which identifies ligands of L-selectin on lymph node high endothelial venules; and
- 15 (e) being sulfation-independent.

2. An isolated and purified glycoprotein and functional analogues thereof as set forth in claim 1 wherein said glycoprotein is a membrane-associated

20 glycoprotein.

3. An isolated and purified glycoprotein and functional analogues thereof as set forth in claim 1 wherein said glycoprotein functions as an adhesion

25 protein ligand.

09358115.072199

4. An isolated and purified glycoprotein and functional analogues thereof as set forth in claim 1 wherein said glycoprotein facilitates attachment of lymphocytes to hematopoietic cells.

5

5. At least one antibody directed against said glycoprotein and functional analogues thereof as set forth in claim 1.

10

6. An antibody as set forth in claim 5 wherein said antibody is a monoclonal antibody.

15

7. A method of targeting cells expressing the glycoprotein as set forth in claim 1 including the steps of:

preparing a monoclonal antibody directed against the glycoprotein as set forth in claim 1,

preparing an immunotoxin utilizing the antibody,

20

exposing a population of cells to said antibodies, and

killing cells bound to the immunotoxin.

09358146-072199

8. The method of claim 7 wherein the toxin is selected from the group consisting of ricin A chain, pseudomonas exotoxin A, diphtheria toxin and chemotherapeutic compounds.

5

9. The method of claim 7 wherein the cells are exposed to the immunotoxin *in vivo*.

10 10. The method of claim 7 further characterized by the cells being selected from the group consisting of leukemic cells, malignant hemopoietic progenitor cells and other malignant cells expressing the glycoprotein.

15 11. A method of selecting for cells expressing the glycoprotein as set forth in claim 1 including the steps of

preparing an antibody directed against the glycoprotein as set forth in claim 1,

20 exposing a population of cells to said antibodies, and

selecting cells bound to the antibody.

09358416.072199

12. A method of selecting against cells expression the glycoprotein as set forth in claim 1 including the steps of:

preparing an antibody directed against the
5 glycoprotein as set forth in claim 1,

exposing a population of cells to said antibodies, and

removing cells bound to the antibody.

10 13. The method of claim 12 wherein said removing step is selected from complement-mediated lysis, panning, cell sorting.

14. A method of regulating hematopoiesis
15 including the step of:

selecting cells with an appropriate level of expression of the glycoprotein as set forth in claim 1 from a patient.

culturing the selected cells, and
20 reinfusing the patient with the expanded selected cell population.

09358115-072199
66T2240-9T18560

15. A method of regulating inflammatory response by interrupting cellular migration into lymph nodes and sites of chronic inflammation including the step of administering to a patient functional analogues or antibody directed against the glycoprotein as set forth in claim 1.

16. The method of claim 15 further characterized by the inflammatory response being as found in the group selected from autoimmune disorders, post-ischemic tissue injury and sepsis.

17. A method of performing an overlay adherence assay by using cell suspensions as a substrate.

18. The method of claim 17 further characterized by preparing the single cell suspension substrate by depositing the single cell suspension on a slide using a modified sample chamber for use in a cytocentrifuge.

19. A method of making a cytocentrifuge sample chamber assembly by connecting together a slide and a sample chamber, the sample chamber including a

09358115-072199
667220-9718560

cell substrate depositing port and fixing the cell substrate depositing port at one of a plurality of positions relative to the slide.

5 20. The method of claim 19 whereby said step of fixing the cell substrate depositing port at one of a plurality of positions relative to the slide is further defined as removing a lateral edge region from an end flange of the sample chamber thereby
10 displacing the sample chamber laterally.

 21. The method of claim 19 whereby said step of fixing the cell substrate depositing port at one of a plurality of positions relative to the slide
15 is further defined as removing a coextensive lower edge region from an end flange and from a rectangular plate of the sample chamber thereby displacing the sample chamber vertically.

20 22. The method of claim 19 whereby the step of fixing the cell substrate depositing port at one of a plurality of positions relative to the slide is further defined as removing a lateral edge region from an end flange of the sample chamber and removing a
25 coextensive lower edge region from an end flange and from a rectangular plate of the sample chamber thereby

0935815-072199

displacing the sample chamber vertically and laterally.

23. A cytocentrifuge sample chamber
5 assembly comprising:

a sample chamber including cell substrate receiving means for receiving a cell substrate and depositing means for depositing a cell substrate on a slide surface during cytocentrifugation; and

10 connecting means for connecting together a slide and said sample chamber and fixing said depositing means at one of a plurality of positions relative to said connecting means.

15 24. A cytocentrifuge sample chamber assembly as set forth in claim 23 wherein said connecting means include an end flange with unequal sized side areas to allow lateral displacement of said depositing means.

20

25 25. A cytocentrifuge sample chamber assembly as set forth in claim 23 wherein said connecting means include a generally rectangular plate disposed normal to and along an end flange with a removed coextensive lower edge region of both said

09358115-072199
66T2240-9T18560

plate and said end flange to allow vertical displacement of said depositing means.

26. A cytocentrifuge sample chamber
5 assembly as set forth in claim 23 wherein said
connecting means include a flat generally rectangular
plate disposed normal to and along an end flange with
a removed coextensive lower edge region of both said
plate and said end flange and unequal sized side areas
10 of said end flange to allow vertical and lateral
displacement of said depositing means.

27. A cytocentrifuge sample chamber
assembly as set forth in claim 23 wherein said
15 depositing means include a discharge port with an
opening through which said cell substrate is deposited
on the slide surface at one of a plurality of
positions.

28. A cytocentrifuge sample chamber
20 assembly as set forth in claim 27 wherein said
receiving means include a funnel interconnected with
said discharge port such that under cytocentrifugation
a cell substrate disposed in said funnel enters said
25 discharge port.

29. A kit consisting of a series of

00358146-072199

incrementally modified sample chambers, said
incremental modifications allowing incremental
vertical and lateral displacement of a sample chamber
in a holder assembly thereby allowing deposition of a
5 cell substrate at one of a plurality of positions on a
slide.

09358116-072199